June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Neurodevelopmental outcomes after intravitreal bevacizumab injection in Japanese preterm infants with retinopathy of prematurity
Author Affiliations & Notes
  • Yuya Fujii
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Mitsuru Arima
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Masato Akiyama
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • YUJIRO MORI
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Kohta Fujiwara
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Hirosuke Inoue
    Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Japan
  • Eiko Seki
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Takahito Nakama
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Shoko Tsukamoto
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Masayuki Ochiai
    Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Japan
  • Shouichi Ohga
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Koh-hei Sonoda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Japan
  • Footnotes
    Commercial Relationships   Yuya Fujii, None; Mitsuru Arima, None; Masato Akiyama, None; YUJIRO MORI, None; Kohta Fujiwara, None; Hirosuke Inoue, None; Eiko Seki, None; Takahito Nakama, None; Shoko Tsukamoto, None; Masayuki Ochiai, None; Shouichi Ohga, None; Koh-hei Sonoda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2178. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuya Fujii, Mitsuru Arima, Masato Akiyama, YUJIRO MORI, Kohta Fujiwara, Hirosuke Inoue, Eiko Seki, Takahito Nakama, Shoko Tsukamoto, Masayuki Ochiai, Shouichi Ohga, Koh-hei Sonoda; Neurodevelopmental outcomes after intravitreal bevacizumab injection in Japanese preterm infants with retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2020;61(7):2178.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We aimed to evaluate neurodevelopmental outcomes in preterm infants who underwent an intravitreal bevacizumab (IVB) injection for type 1 retinopathy of prematurity (ROP).

Methods : In this retrospective analysis, we reviewed the medical records of patients who received ROP screening examinations at Kyushu University Hospital from 2007 to 2017. Among the patients who received IVB or laser photocoagulation (LPC) for type 1 ROP, we listed only infants whose neurodevelopmental examination (the Kyoto Scale of Psychological Development [KSPD]) results at 18 months corrected age were available. Then, the effect of IVB on the developmental quotient (DQ) in each KSPD domain (Postural-Movement, Cognitive-Adaptive, or Language-Social domain) or the overall DQ was investigated by performing linear regression analysis.

Results : Five hundred and thirteen patients were enrolled in this study. Eighty patients developed type 1 ROP and underwent IVB or LPC. Among them, we could obtain the KSPD results from fifty three patients. IVB was significantly associated with neurodevelopmental delay in the Language-Social domain (p=0.01). This association remained even after adjusting for gestational age and birth weight (p=0.03).

Conclusions :
Administration of bevacizumab may introduce a risk of developmental impairment of interpersonal relationships, socializations, and verbal abilities of children. We recommended that preterm infants who received IVB undergo a neurodevelopmental reassessment during their school years or in adulthood.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×